Location out of bounds
Dr. Jack Gorski conducting tests

Clinical Research

The Medical Sciences Institute (MSI) leads development of clinical and translational research at Versiti.

Contact Us

Stephanie Jones

MSI Quality and Research Supervisor

Our clinical investigators, along with scientific colleagues worldwide, find new discoveries, treatments and cures that make significant contributions to patient care locally, nationally and internationally.

As part of Versiti’s effort to advance clinical research, the MSI has established a Clinical Trials and Research Office (CTRO). The mission of the CTRO is to conduct clinical trials and research in a safe, compliant, expedient and cost-effective manner and enhance outstanding patient care.

physician talking to his patient

Clinical Trials

We rely on the participation of human volunteers in order to answer questions about treatments.

Learn More
Dr. Anand Padmanabhan with patient

Translational Science

We leverage our expertise in interventional, observational, epidemiological and laboratory clinical studies.

Learn More


  • Decreased post-surgical bleeding

    Patients undergoing heart surgery often receive Heparin to decrease the incidence of clotting. For some patients, however, Heparin can induce excessive post-surgical bleeding. Versiti researchers created a test for Heparin-induced thrombocytopenia (HIT), so physicians can identify the source of this bleeding and discontinue Heparin therapy.

  • Safer pregnancies

    In certain instances, a pregnant woman’s immune system can react against the fetus and destroy its platelets. This condition is known as Neonatal Alloimmune Thrombocytopenic Purpura (NATP). Versiti researchers were the first to identify the platelet markers most commonly implicated in NATP, and formulated a DNA detection test that has resulted in decreased fetal deaths.

  • More successful transplants

    Versiti researchers were the first to discover certain white cell markers, called HLA markers, that are important to match to maximize the success of a transplant. They then developed genetic typing that allows for more accurate matching of bone marrow donors with patients, decreasing the incidence of rejection.

  • Hope for newborns

    Protein C-deficient newborns do not live long because their blood is unable to properly regulate the clotting process, causing them to have profound systemic clotting. Versiti researchers defined the role of protein C in clot regulation, and created the first successful treatment for protein C-deficient newborns.

  • Safer transfusions

    Patients in need of frequent transfusions can develop reactions to the blood they receive. Through a technique involving the matching of certain markers on platelets, the incidence of reactions following transfusions has decreased.

  • Safer treatment for hemophilia patients

    By early recognition of the risks of pooled product, Versiti researchers helped to reduce the incidence of HIV in this population by providing an alternate product.

  • Extended blood supply

    Versiti researchers have determined methods for improving the quality and quantity of stored platelets. Those needing platelets include surgery patients, organ transplant recipients and patients undergoing chemotherapy.

  • Better treatment for sickle cell patients
    Researchers have participated in studies leading to improved treatments for sickle cell patients. Sickle cell disease impacts about 1 in 400 African Americans.

This website uses cookies to ensure you get the best experience on our website. Learn more